MQB Partners
Level 3, Brandon House, 149 Featherston Street, Wellington, 6011, New Zealand
Overview
MQB Partners is a healthtech investment management firm that invests and manages healthtech investments globally.
- Total investments
- 2
- Lead investments
- 0
- Investments · 12mo
- 1
- Active investors
- 0
Investment portfolio
- Cerevance
Participated · Series C · May 2026
Cerevance uses a proprietary Nuclear Enriched Transcript Sort sequencing (NETSseq) platform to identify drug targets expressed in specific human brain cell types. Its lead investigational candidate, solengepras (CVN424), is a once-daily oral therapy being evaluated in the pivotal Phase 3 ARISE trial, which is fully enrolled with 341 patients. ARISE is a randomized, double-blind, placebo-controlled study assessing solengepras as an adjunctive therapy in patients with motor fluctuations; topline data are expected at the end of Q3 2026. The company also is developing CVN293, a selective oral inhibitor targeting THIK1 (KCNK13). Cerevance announced an oversubscribed $20 million Series C to fund operations through the ARISE readout and to advance its pipeline, extending runway into mid-2027. The company is clinical-stage and based in Boston.
Team
No current team members are available.